CD19-Directed Genetically Modified Autologous T-cell Immunotherapies

DBCAT005665Therapeutic category

Type of immunotherapy that involves the adoptive transfer of T cells that have been genetically modified with a chimeric antigen receptor (CAR) to target CD19. A DrugBank category of 3 drugs. 3 of them are approved.

Drugs: Brexucabtagene autoleucel
Lisocabtagene maraleucel
Obecabtagene autoleucel

What you can answer from here — as of July 20, 2022

3DrugsEach linked to its full drug card

Listed above

1Drug targetEvery drug–target pair in the class, with bond type

10Marketed productsAcross the regions we cover, with dosage forms and routes

1Route of administrationHow the drugs in this class are given

Which targets do CD19-Directed Genetically Modified Autologous T-cell Immunotherapies share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account